This doesnt only affect how long cells survive, but also how well they functionimpacting energy levels, tissue repair, skin quality, immune balance, and overall resilience
The study showed a 13% reduction in major adverse cardiovascular events (MACE), a composite endpoint for cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, in patients treated with liraglutide compared with placebo at a mean follow-up of 3.8 years (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.780.97) and a significant reduction in cardiovascular death (HR 0.78, 95% CI 0.660.93)
Secure Payment Your payments are secure with our private security network
had a protective effect against liver cancer
For a version without annotations, click here.